
doi: 10.1002/ijgo.15092
pmid: 37688299
SynopsisBoth use and cessation of semaglutide constitutes problems prior to and during pregnancy. More problems are expected with increasing use.
semaglutide, Glucagon-Like Peptides, Pregnancy Outcome, Semaglutide, Overweight, untoward fetal outcome, Diabetes Mellitus, Type 2, Pregnancy, risk pregnancy, PCOS, case report, malformations, overweight, Humans, Hypoglycemic Agents, Female, pregnancy
semaglutide, Glucagon-Like Peptides, Pregnancy Outcome, Semaglutide, Overweight, untoward fetal outcome, Diabetes Mellitus, Type 2, Pregnancy, risk pregnancy, PCOS, case report, malformations, overweight, Humans, Hypoglycemic Agents, Female, pregnancy
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 29 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
